Genmab A (GMAB) Restructuring Costs (2024 - 2026)

Genmab A (GMAB) posted Restructuring Costs of -$45.0 million for Q1 2026, down 15.38% on a QoQ basis from -$39.0 million in Q3 2024.

Genmab A (GMAB) Restructuring Costs (2024 - 2026) Analysis & Trends

Genmab A's Restructuring Costs history runs 2 years deep, the most recent figure standing at -$45.0 million for Q1 2026.

Quarterly Restructuring Costs changed N/A year-over-year to -$45.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$120.0 million (changed N/A YoY) and the FY2025 annual result came in at -$185.0 million, down 478.12% from the prior year.
Restructuring Costs was -$45.0 million for Q1 2026 at Genmab A, down from -$39.0 million in the prior quarter.
Across five years, Restructuring Costs topped out at -$36.0 million in Q2 2024 and bottomed at -$45.0 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Genmab A	1.89 Bn	366.92 Mn	831.00 Mn

Download Data